drugset / Trial / NCT04974957
Study of SHR-1701 Plus BP102 in Subjects With Selected Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
The main purpose of this study was to assess the safety,efficacy and pharmacokinetic when combining SHR-1701 and BP102 in participants with advanced or metastatic non-squamous non-small cell lung cancer. To explore the immunogenicity of SHR-1701 and the relationship between corresponding biomarkers and therapeutic effect.
Timeline
- Start
- 2021-08-30
- Primary completion
- 2022-02-28
- Completion
- 2022-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BP102 | Monoclonal antibody | — | Intravenous |
| Subject | Retlirafusp alfa | Protein / enzyme biologic | — | Intravenous |